Lupin Ltd has received tentative approval from the U.S. FDA for its Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, which are bioequivalent to Gilead's Biktarvy Tablets, expected to have annual sales of USD 16,237 million in the U.S. as of July 2025.